首頁 > 市場調查報告書 > 製藥

疫苗感染疾病

市場調查報告書

商品編碼

1827978

人類乳突病毒疫苗市場：疫苗類型、最終用戶、分銷管道、年齡層和性別—2025-2032 年全球預測

Human Papillomavirus Vaccine Market by Vaccine Type, End User, Distribution Channel, Age Group, Gender - Global Forecast 2025-2032

出版日期: 2025年09月30日 | 出版商:

360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄圖表

預計到 2032 年，人類乳突病毒疫苗市場規模將達到 80.5 億美元，複合年成長率為 7.24%。

主要市場統計數據
基準年2024年	46億美元
預計2025年	49.3億美元
預測年份：2032年	80.5億美元
複合年成長率（%）	7.24%

簡潔而引人注目地說明了人類乳突病毒疫苗的發展歷程，包括科學進步、交付挑戰和戰略要點

人類乳突病毒疫苗領域融合了公共衛生優先事項、科學創新和不斷變化的接種模式，這些都定義了當今HPV預防的時代。免疫學和疫苗配方的進步正在提高人類乳突病毒(HPV)疫苗的覆蓋率和保護的持久性，而衛生當局不斷變化的建議正在重新調整目標年齡和補種策略。同時，對公平性、學校疫苗接種計畫以及與青少年健康服務的整合的日益重視，正在將政策討論範圍從臨床有效性擴展到可及性、可接受性和可行性。

同時，相關人員面臨來自供應鏈複雜性和日益多元化的分銷環境的日益成長的營運壓力。製造商、疫苗接種人員和公共衛生規劃人員必須駕馭採購管道、低溫運輸物流和多樣化的醫療點，以保持一致的疫苗接種覆蓋率。清晰的溝通需求進一步加劇了這些動態，以解決疫苗猶豫問題並維持歷史上服務不足的人群的接種率。因此，有效的策略不僅需要臨床證據，還需要切實可行的交付途徑、公共和私人相關人員之間的合作，以及能夠捕捉現實世界績效和公平結果的監測系統。

本執行摘要概述了臨床醫生、政策制定者和商業領袖在將科學前景轉化為人口層面預防時需要考慮的關鍵因素，重點關注結構變化、監管和貿易影響、基於細分的見解以及支持規劃、採購和項目設計中可行決策的實用建議。

深入探討影響整個醫療保健系統人類乳突病毒(HPV)疫苗接種和採用的關鍵臨床、操作和政策變化

由於臨床創新、指南的不斷演變以及更廣泛的衛生系統適應，人類乳突病毒(HPV)疫苗領域正在發生重大變化。多效價疫苗製劑的突破擴大了對其他致癌HPV類型的保護，促使多個司法管轄區發布了更新和補種建議。這些臨床進展，加上生產流程的改進和供應鏈的現代化，正在影響更廣泛疫苗宣傳活動的可近性和可行性。

同時，免疫接種生態系統正在呈現多樣化。傳統的以醫院和診所為基礎的疫苗接種模式正在與以學校為基礎的計劃、以藥房為基礎的疫苗接種服務以及旨在有效為青少年和年輕人接種疫苗的社區外展工作相結合。數位健康平台和電子疫苗接種登記系統正在改善預約安排、提醒和縱向追蹤，從而提高接種完成率。旨在教育猶豫不決的人群和青少年並改善知情同意的策略也在改變公眾情緒和溝通方式。

政策和財政趨勢為這些臨床和營運轉變增添了策略維度。公共資金的擴大、保險公司承保範圍的調整以及創新的採購機制正在改變疫苗的購買和分配方式。總而言之，這些發展反映出一個日益成熟的領域，在這個領域中，臨床有效性、實施科學和系統級協調將決定HPV預防工作的節奏和範圍。

嚴格分析新的進口關稅動態將如何再形成影響疫苗供應的供應鏈經濟、採購行為和生產投資決策。

主要進口國的新關稅或貿易政策調整，可能導致疫苗等生技藥品的供應鏈經濟、採購選擇和分銷策略發生重大變化。關稅會增加出口產品的到岸成本，往往會引發連鎖反應，例如與供應商重新談判、改變庫存緩衝策略以及探索其他採購和生產地點。在固定預算下運作的衛生系統和公共採購機構可以透過優先安排採購週期、調整訂單數量或尋求國內製造合作夥伴來適應變化，以減輕進口關稅的影響。

貿易政策的改變也將影響在岸或近岸產能的誘因。中長期關稅制度的確定性增強將鼓勵製造商評估對區域灌裝和封口設施的投資、與當地生產商的許可協議以及策略聯盟，以減少對跨境運輸的依賴。此類結構性因應措施將提高韌性，但需要調整前置作業時間、資本配置和監管規定。同時，醫院集團和連鎖藥局等私人買家可能會調整合約條款，並採用集中採購和競標模式，以分攤成本並降低單一組織的風險。

從營運角度來看，關稅可能會加劇供應鏈摩擦，因為它會增加物流成本、延長清關時間，並提高文件合規性。企業應透過更深入的情境規劃和增強需求感知能力來應對，以避免缺貨和供應過期。公平性考量也至關重要，因為成本增加可能會對針對低收入者的公共衛生計畫造成不成比例的影響。因此，相關人員應考慮將短期緩解措施與長期結構性投資相結合，以維持疫苗接種的可及性，並最大程度地減少對疫苗接種計畫的干擾。

可操作的細分情報揭示了疫苗類型、照護端、分銷管道、年齡層和性別動態如何推動有針對性的投放策略

以細分市場為重點的洞察揭示了產品屬性、照護端和人群群體如何相互作用，從而影響交付策略和專案成果。以疫苗類型分析時，九價、二價和四價製劑之間的差異會影響臨床組合決策和傳播策略。從最終用戶角度來看，診所、醫院和健康中心各自展現出不同的運作模式：診所優先考慮青少年的便利性和可近性，醫院將疫苗接種與專科和住院服務相結合，而健康中心通常在人口健康工作中主導補種宣傳活動和社區外展活動。

分銷管道動態進一步影響疫苗的可及性和消費行為。醫院藥局提供臨床供應管理並與住院服務相結合；線上藥局擴大了成人疫苗接種者的便利性和覆蓋範圍；零售藥局提供照護現場服務，如果與登記處妥善協調，可以改善疫苗系列的啟動和完成。 9-14 歲年齡層的人群通常受益於與學校和小兒科的合作，而 15-26 歲年齡層的人群則需要透過與大學和性健康服務機構的合作，傳達過渡通訊並製定靈活的接種策略。從歷史上看，優先考慮女性疫苗接種的計畫正在朝著性別中立的方向發展，這反映了不同性別在 HPV 相關疾病方面的共用負擔，因此以性別為中心的分析仍然至關重要。

整合這些細分視角可以支援有針對性的專案設計，使相關人員能夠根據每個群體的獨特需求和行為，客製化產品選擇、分發方式和推廣策略。這種細分可以最佳化服務交付，減少錯失的疫苗接種機會，並改善患者在臨床和非臨床環境中的體驗。

對當地法規環境、交付基礎設施和政策重點將如何改變世界各地的疫苗接種推廣策略進行細緻的評估

區域動態影響監管時間表、採購方式和專案重點，從而決定了疫苗舉措的規劃和實施。在美洲，國家免疫計畫和地方公共衛生部門經常協調以學校為基礎的宣傳活動和大規模採購工作，而私人醫療機構和藥房網路則擴大了都市區和郊區都市區的疫苗接種覆蓋範圍。疫苗的接受程度在地區內部和地區之間都存在差異，因此需要針對青少年和年輕人進行宣傳宣傳活動，並與教育機構和社區組織合作。

歐洲、中東和非洲地區不同的法律規範和資源配置導致了不同的實施路徑。在這個複雜的地區，一些國家採用集中公共資金和強大的國家登記系統來推動持續覆蓋，而另一些國家則側重於分階段推廣、有針對性的高風險干預措施或捐助方支持的項目來擴大覆蓋範圍。在某些情況下，由於物流限制，需要低溫運輸投資和利用婦幼保健平台覆蓋目標族群的綜合服務提供模式。

亞太地區擁有高產能製造業、大規模公共衛生計畫以及快速擴張的私人分銷管道。該地區一些市場擁有強大的國內生產能力，以支持區域供應和出口，而其他市場則依賴國際採購機制，並輔以有針對性的國內採購宣傳活動。在所有地區，跨境合作在監管協調、共同採購和知識共用方面的發展，有助於增強韌性並提高專案交付效率。了解這些區域差異使我們能夠更有效地根據當地營運實際情況調整產品系列、資金籌措機制和交付模式。

製造商、物流合作夥伴和服務提供者如何推動人類乳突病毒(HPV)疫苗計劃中的產品供應、交付效率和證據生成的策略概況

關鍵企業相關人員透過產品系列、製造地和策略夥伴關係關係，影響整個人類乳突病毒(HPV)疫苗生態系統的創新、規模化和通路開發。領先的生物製藥公司正在優先考慮高效能製劑，並投資於製程改進，以提高生產產量、穩定性和低溫運輸相容性。此類投資通常伴隨著生命週期管理計劃，包括擴大標籤範圍、兒科和成人包裝附加檔以及上市後安全警戒承諾，從而增強臨床醫生的信心並促進監管對話。

製造商也正在透過多種製造策略來塑造市場准入，包括內部生產、製造外包以及與區域生產商授權合約。這些複雜性影響前置作業時間、填充和封口能力，以及能否獲得保護買家免受跨境中斷影響的本地供應協議。商業策略包括與全國經銷商、零售連鎖藥局以及專門從事溫控處理和最後一哩配送的物流供應商經銷夥伴關係。同時，與學術機構和非政府組織的合作正在支持實施研究和計畫試點，以收集證據來改善交付模式。

服務供應商和私人診所網路發揮互補作用，將疫苗接種納入青少年和成人的常規護理，而科技公司則提供用於疫苗接種登記的安排、提醒和互通性的數位工具。這些企業層面的活動共同決定了產品的實際可用性、交付管道的效率以及影響疫苗接種方案的接種和完成的支援服務範圍。

為產業參與者提供實用的優先建議，以增強供應彈性、擴大交付管道並加快公平獲得人類乳突病毒(HPV)疫苗。

產業領導者應協同採取一系列行動，使臨床價值、營運彈性和可及性目標保持一致。首先，加強區域製造和填充能力可以降低貿易中斷帶來的脆弱性，並縮短前置作業時間。投資決策應以情境規劃為指導，該規劃評估成本、監管複雜性和夥伴關係潛力。其次，上市公司和公共採購者應擴大與其他交付管道（包括藥房和學校專案）的合作，並將這些管道與註冊整合和數位化依從性工具相結合，以提高系列完成率。

第三，包括製造商、相關人員、學術合作夥伴和社區組織在內的相關人員聯盟，可以透過實證宣傳宣傳活動和醫療保健提供者教育來促進疫苗的接受。這些聯盟應優先考慮疫苗益處、安全性和建議接種時間表的透明度，以消除猶豫，並增強臨床醫生為不同年齡層接種疫苗的信心。第四，採用集中採購、靈活合約條款和風險分擔機制的採購方法，有助於在財政緊張的環境下維持疫苗的可及性，並向供應商提供可預測的需求訊號。

最後，領導者應將推廣，並有系統地解決交通、費用、知情同意流程和門診時間等獲得疫苗的障礙。透過將供應面投資與需求產生策略和績效指標結合，各機構能夠持續改善疫苗的發放，使其超越短期宣傳活動週期。

透明且可複製的調查方法框架，結合文獻綜合、相關人員參與和政策分析，以支持可行的方案見解

本分析綜合了同行評審文獻、監管通報、疫苗產品標籤和公共衛生指南文件的證據，並輔以對臨床醫生、採購相關人員和分銷相關人員的利益相關者訪談。調查方法結合了定性綜合和比較政策評估，以揭示臨床屬性、供應途徑和區域因素如何相互作用並影響計畫實施。在適當情況下，透過諮詢在物流、低溫運輸管理和傳播策略方面提供一線觀點的專家，檢驗了這些見解。

對資料來源進行了最後覆核以確保一致性，並納入了最新的監管決策和指南更新以確保相關性。貿易和關稅影響的考量是基於公開的貿易政策公告和物流成本組成，營運影響的探討則是基於供應鏈最佳實踐和疫苗宣傳活動案例研究。這種方法強調可操作的洞察而非數值預測，並強調證據選擇的透明度。它也強調可重複性，使決策者能夠根據自身組織情況調整分析框架。

局限性包括不同司法管轄區的項目實施差異，以及不斷變化的監管指導和採購安排。為了緩解這些局限性，本分析以韌性、可及性和相關人員協作等強力的原則為基礎，並強調了在大規模部署之前建議進行本地檢驗和營運試點的領域。

結論性綜合強調了導致臨床進步、醫療保健提供系統和以公平為重點的實施的整合策略，以促進永續的預防結果。

綜合證據表明，HPV預防的進展將取決於臨床創新、供應鏈開發和服務交付設計等方面的協調行動。疫苗成分和製造流程的進步為更廣泛的保護開闢了新的可能性，但這些技術進步必須與供應系統、數據互通性和有針對性的推廣的投資相匹配，才能實現覆蓋率的顯著提升。政策選擇和採購慣例對疫苗的可近性有重大影響，而貿易和物流的考量則決定了產品在醫療點的實際可近性。

因此，從證據到影響力的轉變需要整合策略。將多樣化的分發管道與強大的數位工具和註冊整合相結合的專案更有可能實現系列完成和持續推廣。同樣重要的是，要致力於以公平為重點的專案設計，減少服務不足人口的障礙，並利用教育、基層醫療和社區組織方面的夥伴關係。簡而言之，永續預防的道路既是技術性的，也是系統性的。它依賴於透過正確的管道分發正確的產品，並以正確的政策和社區信任為支撐。

優先考慮供應彈性、多樣化分銷管道和有針對性的需求刺激的決策者將最有能力將臨床進展轉化為可衡量的公共衛生成果，並持續減輕 HPV 相關疾病的負擔。

九價人類乳突病毒(HPV)疫苗的普及將推動已開發市場的競爭和定價趨勢
新興國家擴大國家疫苗接種計畫可提高青少年人類乳突病毒(HPV)疫苗率
正在研究單劑量人類乳突病毒(HPV)疫苗療法，以提高依從性並降低成本
疫苗製造商與政府建立策略夥伴關係，進行大規模人類乳突病毒(HPV)疫苗宣傳活動
整合數位健康平台，追蹤人類乳突病毒(HPV)疫苗接種覆蓋率並提高患者依從性
增加對下一代人類乳突病毒(HPV)疫苗的投資，旨在擴大疫苗株覆蓋範圍並拓展治療應用
農村地區低溫運輸物流挑戰影響人類乳突病毒(HPV)疫苗分發與取得
公私合營擴大，透過針對性的宣傳計畫解決人類乳突病毒(HPV)疫苗猶豫問題

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 人類乳突病毒疫苗市場（依疫苗類型）

9價
二價
四價

9. 人類乳突病毒疫苗市場（按最終用戶）

診所
醫院
公共衛生中心

10. 人類乳突病毒疫苗市場（按分銷管道）

醫院藥房
網路藥局
零售藥局

11. 人類乳突病毒疫苗市場（依年齡層）

15至26歲
27歲或以上
9至14歲

12. 人類乳突病毒疫苗市場（依性別）

女士
男性

13. 人類乳突病毒疫苗市場（按地區）

美洲
- 北美洲
- 拉丁美洲
歐洲、中東和非洲
- 歐洲
- 中東
- 非洲
亞太地區

14. 人類乳突病毒疫苗市場（依類別）

ASEAN
GCC
EU
BRICS
G7
NATO

15. 人類乳突病毒疫苗市場（依國家）

美國
加拿大
墨西哥
巴西
英國
德國
法國
俄羅斯
義大利
西班牙
中國
印度
日本
澳洲
韓國

第16章競爭格局

2024年市佔率分析
2024年FPNV定位矩陣
競爭分析
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Shanghai Zerun Biotech Co., Ltd.
- Xiamen Innovax Biotech Co., Ltd.
- Shenzhen Kangtai Biological Products Co., Ltd.
- Walvax Biotechnology Co., Ltd.
- Beijing Zhifei Lvzhu Biopharma Co., Ltd.
- Panacea Biotec Ltd.

簡介目錄圖表

Product Code: MRR-436B79517C6E

The Human Papillomavirus Vaccine Market is projected to grow by USD 8.05 billion at a CAGR of 7.24% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 4.60 billion
Estimated Year [2025]	USD 4.93 billion
Forecast Year [2032]	USD 8.05 billion
CAGR (%)	7.24%

A concise and compelling orientation to the evolving human papillomavirus vaccine environment that frames scientific advances, delivery challenges, and strategic imperatives

The human papillomavirus vaccine landscape represents a convergence of public health priorities, scientific innovation, and shifting delivery paradigms that together define the current era of HPV prevention. Advances in immunology and vaccine composition have improved the breadth of type coverage and durability of protection, while evolving recommendations from health authorities have recalibrated target age groups and catch-up strategies. Concurrently, greater emphasis on equity, school-based vaccination programs, and integration with adolescent health services has expanded the policy conversation beyond clinical efficacy to include access, acceptability, and implementation feasibility.

At the same time, stakeholders face intensifying operational pressure from supply chain complexity and an increasingly multifaceted distribution environment. Manufacturers, vaccinators, and public health planners must navigate procurement channels, cold-chain logistics, and diverse points of care in order to maintain consistent coverage. These dynamics are amplified by the need for clear communication to address vaccine hesitancy and to sustain uptake among populations historically underserved by preventive services. As a result, effective strategy requires not only clinical evidence but also pragmatic pathways for delivery, stakeholder alignment across public and private sectors, and monitoring systems that capture real-world performance and equity outcomes.

This executive summary frames the essential considerations for clinicians, policy-makers, and commercial leaders as they seek to translate scientific promise into population-level prevention. It focuses on structural shifts, regulatory and trade influences, segmentation-driven insights, and practical recommendations that support actionable decisions in planning, procurement, and program design.

An incisive exploration of the major clinical, operational, and policy transformations reshaping HPV vaccine delivery and adoption across health systems

The HPV vaccine landscape has undergone transformative shifts driven by clinical innovation, evolving guidelines, and broader health system adaptation. Breakthroughs in multivalent vaccine formulations have expanded protective coverage against additional oncogenic HPV types, prompting updates to immunization schedules and catch-up recommendations in several jurisdictions. These clinical advances have been matched by improved manufacturing processes and supply chain modernization, which together influence availability and the feasibility of broader immunization campaigns.

Simultaneously, the ecosystem of delivery has diversified. Traditional hospital- and clinic-centered vaccination models are being supplemented by school-based programs, pharmacy-administered services, and community outreach initiatives that aim to reach adolescents and young adults more effectively. Digital health platforms and electronic immunization registries enhance the capacity for appointment scheduling, reminders, and longitudinal tracking, thereby improving series completion rates. Public sentiment and communication dynamics have also evolved, with targeted education efforts and engagement strategies designed to address hesitancy and improve informed consent among caregivers and adolescents.

Policy and financing trends have added a strategic dimension to these clinical and operational shifts. Expanded public funding, insurer coverage adjustments, and innovative procurement mechanisms have altered how vaccines are purchased and distributed, while regulatory harmonization in some regions has accelerated approval pathways for next-generation products. Taken together, these developments reflect a maturing field in which clinical efficacy, implementation science, and systems-level coordination determine the pace and reach of HPV prevention efforts.

A rigorous analysis of how new import tariff dynamics reshape supply chain economics, procurement behavior, and production investment decisions affecting vaccine accessibility

The imposition of new tariff measures and trade policy adjustments by a major importer can create material changes in supply chain economics, procurement choices, and distribution strategies for biologics such as vaccines. Tariffs increase landed costs for exported products, which often triggers a cascade of responses including renegotiated supplier agreements, changes in inventory buffering strategies, and a search for alternative sourcing and manufacturing locations. Health systems and public purchasers that operate under fixed budgets may adapt by prioritizing procurement cycles, altering order quantities, or seeking domestic manufacturing partnerships to mitigate exposure to import duties.

Trade policy shifts also affect the incentives for onshoring or nearshoring production capacity. Greater certainty around medium- to long-term tariff regimes encourages manufacturers to evaluate investment in regional fill-and-finish facilities, licensing agreements with local producers, and strategic alliances that reduce dependence on cross-border shipments. These structural responses can improve resilience but require lead time, capital allocation, and regulatory alignment. In parallel, private-sector buyers such as hospital groups and pharmacy chains may adjust contracting terms and embrace pooled procurement or tender models that spread costs and reduce individual institutional risk.

Operationally, tariffs can amplify supply chain friction by increasing the significance of logistics costs, customs clearance timelines, and documentation compliance. Organizations respond through more intensive scenario planning and strengthening of demand-sensing capabilities to avoid stockouts or expiries. Equity considerations are also pivotal, as increased costs can disproportionately affect public health programs serving low-income communities. As a result, stakeholders should consider a combination of short-term mitigation tactics and long-term structural investments to preserve access and minimize disruption to immunization schedules.

Actionable segmentation intelligence revealing how vaccine type, points of care, distribution channels, age cohorts, and gender dynamics drive targeted delivery strategies

Segment-focused insights reveal how product characteristics, points of care, and population cohorts interact to shape delivery strategies and program outcomes. When analyzed by vaccine type, the differentiation among nine-valent, bivalent, and quadrivalent formulations informs both clinical portfolio decisions and communication strategies, since broader type coverage influences recommendations for age-based vaccination and targeted outreach to high-risk groups. Considering the end user dimension, clinics, hospitals, and public health centers each present distinct operational profiles: clinics may prioritize convenience and adolescent access, hospitals may integrate vaccination with specialty and inpatient services, and public health centers often lead catch-up campaigns and community outreach in population health initiatives.

Distribution channel dynamics further affect access and consumer behavior. Hospital pharmacies provide controlled clinical supply and integration with inpatient services, online pharmacies expand convenience and reach for adult vaccination seekers, and retail pharmacies offer point-of-care accessibility that can improve series initiation and completion when properly coordinated with registries. Age group segmentation underscores the need for tailored strategies: the 9-14 years cohort often benefits from school-based and pediatric touchpoints, the 15-26 years group requires transition-oriented messaging and flexible delivery options linked to college and sexual health services, while individuals 27 years and above need clearer risk communication and adult immunization pathways. Gender-focused analysis remains essential, as historical programs that prioritized female vaccination are evolving toward gender-neutral approaches that reflect the shared burden of HPV-related disease across all sexes.

Integrating these segmentation lenses supports targeted program design, enabling stakeholders to align product selection, distribution modalities, and outreach tactics with the distinct needs and behaviors of each group. This granularity aids in optimizing service delivery, reducing missed opportunities for vaccination, and improving the patient experience across clinical and non-clinical settings.

A nuanced appraisal of how regional regulatory environments, delivery infrastructures, and policy priorities alter vaccination rollout strategies across global territories

Regional dynamics influence regulatory timelines, procurement approaches, and programmatic priorities in ways that shape how vaccination initiatives are planned and executed. Across the Americas, national immunization programs and subnational public health authorities often coordinate school-based campaigns and large-scale procurement activities, while private providers and pharmacy networks expand access in urban and peri-urban centers. Vaccine acceptance varies within and between jurisdictions, prompting tailored communication campaigns and partnerships with educational institutions and community organizations to reach adolescents and young adults.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and resource allocation creates distinct implementation pathways. Some countries in this complex region employ centralized public funding and robust national registries to drive consistent coverage, whereas others focus on phased rollouts, targeted high-risk interventions, or donor-supported programs to extend reach. Logistical constraints in certain contexts necessitate cold-chain investments and integrated service delivery models that leverage maternal and child health platforms to reach eligible cohorts.

The Asia-Pacific region demonstrates a mix of high-capacity manufacturing, large-scale public health initiatives, and rapidly expanding private-sector distribution channels. Several markets in this region have strong domestic production capabilities that support regional supply and export, while others rely on international procurement mechanisms supplemented by targeted domestic campaigns. Across all regions, cross-border collaboration on regulatory harmonization, pooled procurement, and knowledge sharing enhances resilience and contributes to more efficient program delivery. Understanding these regional nuances enables more effective alignment of product portfolios, financing mechanisms, and delivery models with local operational realities.

A strategic overview of how manufacturers, logistics partners, and service providers drive product availability, delivery efficiency, and evidence generation across HPV vaccination programs

Key corporate actors influence innovation, scale-up, and channel development across the HPV vaccine ecosystem through product portfolios, manufacturing footprint, and strategic partnerships. Leading biopharmaceutical firms prioritize extended valency formulations and invest in process improvements that enhance production yield, stability, and cold-chain compatibility. These investments are often accompanied by lifecycle management programs that include label expansions, pediatric and adult indication dossiers, and post-marketing safety surveillance commitments that inform clinician confidence and regulatory dialogue.

Manufacturers also shape access through diversified manufacturing strategies that encompass in-house production, contract manufacturing organizations, and licensing arrangements with regional producers. This complexity affects lead times, fill-and-finish capacity, and the potential for local supply agreements that insulate purchasers from cross-border disruptions. Commercial strategies extend to distribution partnerships with national distributors, retail pharmacy chains, and logistics providers that specialize in temperature-controlled handling and last-mile delivery. In parallel, collaborations with academic institutions and non-governmental organizations support implementation research and programmatic pilots that generate evidence to refine delivery models.

Service providers and private clinic networks play complementary roles by integrating vaccination into routine adolescent and adult care pathways, while technology firms contribute digital tools for scheduling, reminders, and immunization registry interoperability. Collectively, these company-level activities determine the practical availability of products, the efficiency of delivery channels, and the breadth of supporting services that influence uptake and completion of vaccination regimens.

Practical and prioritized recommendations for industry participants to strengthen supply resilience, broaden delivery channels, and accelerate equitable HPV vaccine access

Industry leaders should pursue a coordinated set of actions that align clinical value, operational resilience, and access objectives. First, strengthening regional manufacturing and fill-and-finish capacity can reduce vulnerability to trade disruptions and shorten lead times. Investment decisions should be guided by scenario planning that evaluates cost, regulatory complexity, and partnership potential. Second, companies and public purchasers should expand engagement with alternative delivery channels, including pharmacies and school-based programs, and pair these channels with registry integration and digital adherence tools to improve series completion.

Third, stakeholder coalitions that include manufacturers, payers, academic partners, and community organizations can accelerate acceptance through evidence-informed communication campaigns and provider education. These coalitions should prioritize transparency about benefits, safety, and recommended schedules to address hesitancy and to increase clinician confidence in administering vaccines to diverse age cohorts. Fourth, procurement approaches that incorporate pooled purchasing, flexible contracting terms, and risk-sharing mechanisms will help preserve access in constrained fiscal environments and provide predictable demand signals for suppliers.

Finally, leaders should embed equity metrics into program design and measurement frameworks to ensure that underserved populations receive prioritized outreach and that barriers to access-transportation, cost, consent processes, and clinic hours-are systematically addressed. By combining supply-side investments with demand-generation strategies and performance metrics, organizations can create durable improvements in vaccine delivery that extend beyond short-term campaign cycles.

A transparent and replicable methodological framework combining literature synthesis, stakeholder engagement, and policy analysis to underpin actionable programmatic insights

This analysis synthesizes evidence from peer-reviewed literature, regulatory communications, vaccine product labels, and public health guidance documents, complemented by stakeholder interviews with clinicians, procurement officials, and distribution partners. The methodology integrates qualitative synthesis with comparative policy assessment to illuminate how clinical attributes, delivery channels, and regional factors interact to affect program implementation. Where appropriate, insights were validated through expert consultations that provided frontline perspectives on logistics, cold-chain management, and communication strategies.

Data sources were cross-checked for consistency and recent regulatory decisions and guideline updates were incorporated to ensure relevance. Trade and tariff implications were examined using publicly available trade policy announcements and logistics cost components, while operational implications were informed by supply chain best practices and case studies of immunization campaigns. The approach emphasizes transparency in evidence selection, with an explicit focus on actionable findings rather than numerical projections, and prioritizes replicability so that decision-makers can adapt the analytical framework to their organizational context.

Limitations include variability in programmatic implementation across jurisdictions and the evolving nature of regulatory guidance and procurement arrangements. To mitigate these limitations, the analysis grounds recommendations in robust principles of resilience, access, and stakeholder alignment and highlights areas where localized validation and operational piloting are advisable prior to large-scale roll-out.

A conclusive synthesis emphasizing integrated strategies that connect clinical advances, delivery systems, and equity-focused implementation to drive sustained prevention outcomes

The collective evidence underscores that progress in HPV prevention depends on coordinated action across clinical innovation, supply chain architecture, and service delivery design. Advances in vaccine composition and manufacturing open new possibilities for broader protection, but these technical gains must be matched by investment in delivery systems, data interoperability, and targeted outreach to achieve meaningful improvements in coverage. Policy choices and procurement practices have an outsized influence on access, while trade and logistics considerations shape the practical availability of products at points of care.

Moving from evidence to impact therefore requires integrated strategies that align finance, operations, and community engagement. Programs that couple diverse distribution channels with robust digital tools and registry integration demonstrate higher potential for series completion and sustained uptake. Equally important is a commitment to equity-minded program design that reduces barriers for underserved populations and leverages partnerships across education, primary care, and community organizations. In sum, the path to durable prevention is both technical and systemic: it depends on the right products, distributed through the right channels, supported by the right policies and community trust.

Decision-makers who prioritize supply resilience, channel diversification, and targeted demand-generation will be best positioned to translate clinical advances into measurable public health outcomes and sustained reductions in HPV-related disease burden.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Rising adoption of 9-valent HPV vaccines driving competition and pricing dynamics in developed markets
5.2. Expansion of national immunization programs in emerging economies boosting HPV vaccine uptake among adolescents
5.3. Ongoing research into single-dose HPV vaccine regimens aiming to improve compliance and reduce costs
5.4. Strategic partnerships between vaccine manufacturers and governments for large-scale HPV vaccination campaigns
5.5. Integration of digital health platforms to track HPV vaccination coverage and improve patient adherence
5.6. Increasing investment in next-generation HPV vaccines targeting broader strain coverage and therapeutic applications
5.7. Challenges of cold chain logistics in rural regions affecting HPV vaccine distribution and access
5.8. Growing public-private initiatives to address HPV vaccine hesitancy through targeted awareness programs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Papillomavirus Vaccine Market, by Vaccine Type

8.1. 9-Valent
8.2. Bivalent
8.3. Quadrivalent

9. Human Papillomavirus Vaccine Market, by End User

9.1. Clinics
9.2. Hospitals
9.3. Public Health Centers

10. Human Papillomavirus Vaccine Market, by Distribution Channel

10.1. Hospital Pharmacies
10.2. Online Pharmacies
10.3. Retail Pharmacies

11. Human Papillomavirus Vaccine Market, by Age Group

11.1. 15-26 Years
11.2. 27 Years And Above
11.3. 9-14 Years

12. Human Papillomavirus Vaccine Market, by Gender

12.1. Female
12.2. Male

13. Human Papillomavirus Vaccine Market, by Region

13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
13.3. Asia-Pacific

14. Human Papillomavirus Vaccine Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Human Papillomavirus Vaccine Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. Competitive Landscape

16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
- 16.3.1. Merck & Co., Inc.
- 16.3.2. GlaxoSmithKline plc
- 16.3.3. Shanghai Zerun Biotech Co., Ltd.
- 16.3.4. Xiamen Innovax Biotech Co., Ltd.
- 16.3.5. Shenzhen Kangtai Biological Products Co., Ltd.
- 16.3.6. Walvax Biotechnology Co., Ltd.
- 16.3.7. Beijing Zhifei Lvzhu Biopharma Co., Ltd.
- 16.3.8. Panacea Biotec Ltd.

簡介目錄圖表

LIST OF FIGURES

FIGURE 1. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2024 VS 2032 (%)
FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 13. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 14. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 15. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 17. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 18. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 19. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 20. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 22. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 23. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 24. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 25. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 26. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 27. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 29. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

TABLE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY REGION, 2025-2032 (USD MILLION)
TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY GROUP, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY GROUP, 2025-2032 (USD MILLION)
TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-VALENT, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2025-2032 (USD MILLION)
TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY GROUP, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY GROUP, 2025-2032 (USD MILLION)
TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY REGION, 2025-2032 (USD MILLION)
TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY GROUP, 2025-2032 (USD MILLION)
TABLE 23. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY QUADRIVALENT, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 25. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 27. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
TABLE 29. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 31. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 33. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
TABLE 35. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 37. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 39. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
TABLE 41. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 43. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 45. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 47. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
TABLE 49. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 51. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 53. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
TABLE 55. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 57. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 59. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
TABLE 61. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 63. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 65. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 67. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY REGION, 2025-2032 (USD MILLION)
TABLE 69. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 71. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 15-26 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 73. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
TABLE 75. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 77. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 27 YEARS AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 79. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY REGION, 2025-2032 (USD MILLION)
TABLE 81. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 83. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY 9-14 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 85. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 87. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
TABLE 89. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 91. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 93. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
TABLE 95. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 97. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 99. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
TABLE 101. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
TABLE 103. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 105. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 107. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 109. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 111. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 113. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 115. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 116. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 117. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 119. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 121. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 122. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 123. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 124. NORTH AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 125. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 126. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 127. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 128. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 129. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 131. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 133. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 134. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 135. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 136. LATIN AMERICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 149. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 150. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 151. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 152. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 153. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 155. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 157. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 159. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 160. EUROPE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 161. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 162. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 163. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 164. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 165. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 167. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 169. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 170. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 171. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 172. MIDDLE EAST HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 173. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 174. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 175. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 176. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 177. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 179. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 181. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 183. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 184. AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 188. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 191. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 193. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 194. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 196. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 197. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 198. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 199. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 201. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 202. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 203. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 205. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 207. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 208. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 209. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 210. ASEAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 211. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 212. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 213. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 214. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 215. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 217. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 219. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 220. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 221. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 222. GCC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 224. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 226. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 232. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 234. EUROPEAN UNION HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 235. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 236. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 237. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 238. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 239. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 241. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 243. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 244. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 245. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 246. BRICS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 247. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 248. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 249. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 250. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 251. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 253. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 255. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 256. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 257. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 258. G7 HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 259. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 260. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 261. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 262. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 263. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 265. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 267. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 268. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 269. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 270. NATO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 271. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 272. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 273. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 274. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 275. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 277. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 279. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 281. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 282. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 283. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 284. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 285. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 287. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 289. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 290. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 291. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 292. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 293. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 294. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 295. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 297. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 299. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 300. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 301. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 302. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 303. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 305. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 307. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
TABLE 309. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 310. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
TABLE 311. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 312. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
TABLE 315. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, B